Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer

Journal of Medicinal Chemistry

Volumn 53, Issue 15, 2010, Pages 5749-5758

  Hu, Qingzhong ^a   Jagusch, Carsten ^b   Hille, Ulrike E ^a   Haupenthal, Jörg ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Dottikon Exclusive Synthesis AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4' (PYRIDIN 4 YLMETHYL)BIPHENYL 3,4 DIOL; ABIRATERONE; ALDOSTERONE SYNTHASE; AROMATASE; BIPHENYL DERIVATIVE; BIPHENYLMETHYLENE DERIVATIVE; CYTOCHROME P450 11B1; CYTOCHROME P450 17; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; KETOCONAZOLE; METYRAPONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; ENZYME SPECIFICITY; HUMAN; IC 50; PROSTATE CANCER; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION;

ANDROGEN ANTAGONISTS; ANIMALS; BIPHENYL COMPOUNDS; CELL LINE; CRICETINAE; CRICETULUS; HUMANS; IMIDAZOLES; MALE; MICROSOMES; PROSTATIC NEOPLASMS; PYRIDINES; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; TESTIS;

EID: 77955388983     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100317b     Document Type: Article

References (52)

1. Geller, J. Basis for hormonal management of advanced prostate cancer Cancer 1993, 71, 1039-1045
2. Huhtaniemi, I.; Nikula, H.; Parvinen, M.; Rannikko, S. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer Am. J. Clin. Oncol. 1988, 11 (Suppl. 1) S11-S15
3. Labrie, F.; Dupont, A.; Belanger, A.; Cusan, L.; Lacourciere, Y.; Monfette, G.; Laberge, J. G.; Emond, J. P.; Fazekas, A. T.; Raynaud, J. P.; Husson, J. M. New hormonal therapy in prostatic carcinoma: combined treatment with LHRH agonist and an antiandrogen Clin. Invest. Med. 1982, 5, 267-275
4. Hara, T.; Miyazaki, J.; Araki, H.; Yamaoka, M.; Kanzaki, N.; Kusaka, M.; Miyamoto, M. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome Cancer Res. 2003, 63, 149-153
5. Zhao, X. Y.; Malloy, P. J.; Krishnan, A. V.; Swami, S.; Navone, N. M.; Peehl, D. M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat. Med. 2000, 6, 703-706
6. Chung, B. C.; Picardo-Leonard, J.; Hanui, M.; Bienkowski, M.; Hall, P. F.; Shively, J. E.; Miller, W. L. Cytochrome P450c17(steroid 17?-hydroxylase/C17,20-lyase): cloning of human adrenal and testis cDNA indicates the same gene is expressed in both tissues Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 407-411
7. Reed, A. B.; Parekh, D. J. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer Curr. Opin. Urol. 2009, 19, 238-242
8. Picard, F.; Schulz, T.; Hartmann, R. W. 5-Phenyl substituted 1-methyl-2-pyridones and 4?-substituted biphenyl-4-carboxylic acids: synthesis and evaluation as inhibitors of steroid-5?-reductase type 1 and 2 Bioorg. Med. Chem. 2002, 10, 437-448
9. Baston, E.; Palusczak, A.; Hartmann, R. W. 6-Substituted 1 H -quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5? reductases types 1 and 2 Eur. J. Med. Chem. 2000, 35, 931-940
10. Palmgren, J. S.; Karavadia, S. S.; Wakefield, M. R. Unusual and underappreciated: small cell carcinoma of the prostate Semin. Oncol. 2007, 34, 22-29
11. Rajec, J.; Mego, M.; Sycova-mila, Z.; Obertova, J.; Brozmanova, K.; Mardiak, J. Paraneoplastic Cushing's syndrome as the first sign of progression of prostate cancer Bratisl. Lek. Listy 2008, 109, 362-363
12. Kataoka, K.; Akasaka, Y.; Nakajima, K.; Nagao, K.; Hara, H.; Miura1, K.; Ishii, N. Cushing syndrome associated with prostatic tumor adrenocorticotropic hormone (ACTH) expression after maximal androgen blockade therapy Int. J. Urol. 2007, 14, 436-439
13. Hussein, W. I.; Kowalyk, S.; Hoogwerf, B. J. Ectopic adrenocorticotropic hormone syndrome caused by metastatic carcinoma of the prostate: therapeutic response to ketoconazole Endocr. Pract. 2002, 8, 381-384
14. Lamberts, S. W. J.; Uitterlinden, P.; De Jong, F. H. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analog Cancer Res. 1988, 48, 6063-6068
15. Eklund, J.; Kozloff, M.; Vlamakis, J.; Starr, A.; Mariott, M.; Gallot, L.; Jovanovic, B.; Schilder, L.; Robin, E.; Pins, M.; Bergan, R. C. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer Cancer 2006, 106, 2459-2465
16. 17?20-lyase (P450 17) J. Med. Chem. 2000, 43, 4437-4445
17. 17,20-lyase (P450 17) Bioorg. Med. Chem. 1996, 4, 1447-1453
18. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C. O.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. H. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model J. Med. Chem. 2005, 48, 2972-2984
19. l7,20- lyase): potential agents for the treatment of prostatic cancer J. Med. Chem. 1995, 38, 2463-2471
20. Attard, G.; Reid, A. H. M.; A'Hern, R.; Parker, C.; Oommen, N. B.; Folkerd, E.; Messiou, C.; Molife, L. R.; Maier, G.; Thompson, E.; Olmos, D.; Sinha, R.; Lee, G.; Dowsett, M.; Kaye, S. B.; Dearnaley, D.; Kheoh, T.; Molina, A.; de Bono, J. S. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J. Clin. Oncol. 2009, 27, 3742-3748
21. Wächter, G. A.; Hartmann, R. W.; Sergejew, T.; Grün, G. L.; Ledergerber, D. Tetrahydronaphthalenes: Influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17 J. Med. Chem. 1996, 39, 834-841
22. Chan, F. C. Y.; Potter, G. A.; Barrie, S. E.; Haynes, B. P.; Rowlands, M. G.; Houghton, J.; Jarman, M. 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450 17? (17?-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer J. Med. Chem. 1996, 39, 3319-3323
23. Wachall, B. G.; Hector, M.; Zhuang, Y.; Hartmann, R. W. Imidazole substituted biphenyls: A new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer Bioorg. Med. Chem. 1999, 7, 1913-1924
24. Leroux, F.; Hutschenreuter, T. U.; Charriere, C.; Scopelliti, R.; Hartmann, R. W. N -(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution? Helv. Chim. Acta 2003, 86, 2671-2686
25. Hutschenreuter, T. U.; Ehmer, P. E.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 Inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32
26. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modeling studies of methyleneimidazole substituted biaryls as inhibitors of human 17?-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure Bioorg. Med. Chem. 2008, 16, 1992-2010
27. Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17-hydroxylase-17,20-lyase (CYP17). Part II: Core rigidification and influence of substituents at the methylene bridge Bioorg. Med. Chem. 2008, 16, 7715-7727
28. Hille, U. E.; Hu, Q.; Vock, C.; Negri, M.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Novel CYP17 inhibitors: synthesis, biological evaluation, structure?activity relationships and modeling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls Eur. J. Med. Chem. 2009, 44, 2765-2775
29. Hu, Q.; Negri, M.; Olgen, S.; Hartmann, R. W. The role of fluorine substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma ChemMedChem 2010, 5, 899-910
30. Hu, Q.; Yin, L.; Jagusch, C.; Hille, U. E.; Hartmann, R. W. Isopropylidene substitution increases activity and selectivity of biphenyl methylene 4-pyridine type CYP17 inhibitors J. Med. Chem. 2010, 53, 5049-5053
31. Hille, U. E.; Hu, Q.; Pinto-Bazurco Mendieta, M. A. E.; Bartels, M.; Vock, C. A.; Lauterbach, T.; Hartmann, R. W. Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile C. R. Chim. 2009, 12, 1117-1126
32. Hartmann, R. W.; Bayer, H.; Grün, G. Aromatase inhibitors. Syntheses and structure?activity studies of novel pyridyl-substituted indanones, indans, and tetralins J. Med. Chem. 1994, 37, 1275-1281
33. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R. W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors J. Med. Chem. 2004, 47, 6792-6803
34. Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller, B.; Piessard-Robert, S.; Le Baut, G.; Hartmann, R. W.; Palzer, M. Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1 H -indoles and 3-(1-azoly1-1- phenylmethyl)-1 H -indoles as inhibitors of P450 arom Arch. Pharm. (Weinheim, Ger.) 1997, 330, 141-145
35. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 2006, 49, 4777-4780
36. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1 H -quinolin-2-one derivatives J. Med. Chem. 2008, 51, 8077-8087
37. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
38. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1563-1575 (Pubitemid 40364563)
39. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylene tetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1796-1805 (Pubitemid 40396312)
40. Temple, T. E.; Liddle, G. W. Inhibitors of adrenal steroid biosynthesis Annu. Rev. pharmacol. 1970, 10, 199-218
41. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)- lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63
42. Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 chinese hamster cells Endocr. Res. 1995, 21, 443-448
43. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179
44. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones J. Med. Chem. 1986, 29, 1362-1369
45. White, P. C.; Curnow, K. M.; Pascoe, L. Disorders of steroid 11β-hydroxylase isozymes Endocr. Rev. 1994, 15, 421-38
46. Vandenput, L.; Ohlsson, C. Estrogens as regulators of bone health in men Nat. Rev. Endocrinol. 2009, 5, 437-43
47. Hill, R. A.; Boon, W. C. Estrogens, brain, and behavior: lessons from knockout mouse models Semin. Reprod. Med. 2009, 27, 218-228
48. Eigen, M. Structures of Biomolecules. In Introduction to Molecular Biophysics; Tuszynski, J.; Kurzynski, M., Eds.; CRC Press LLC: Boca Raton, FL, 2003; pp 52 - 59.
49. Richard, M.; Zoran, R. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
50. Andrea, C.; Laura, B. M.; Anna, M.; Michela, R.; Vincenzo, T.; Maurizio, R.; Carlo, M. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
51. Marco, R.; Chiara, U. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis Curr. Pharm. Des. 2009, 15, 2946-2957
52. Richard, M. Selectively nonselective kinase inhibition: striking the right balance J. Med. Chem. 2010, 53, 1413-1437